Eliem Therapeutics, Inc.

Equities

ELYM

US28658R1068

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
2.74 USD -0.72% Intraday chart for Eliem Therapeutics, Inc. +0.37% +1.48%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Harpoon Therapeutics Appoints Chief Legal Officer, Chief People Officer MT
Eliem Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Eliem Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Eliem Therapeutics Drops Kv7 Program, Explores Strategic Alternatives MT
Eliem Therapeutics Plans to Explore Strategic Alternatives CI
Eliem Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Eliem Therapeutics, Inc. Announces Executive Changes CI
Eliem Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Eliem Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
North American Morning Briefing : Stock Futures -3- DJ
HC Wainwright Downgrades Eliem Therapeutics to Neutral From Buy MT
Erin Lavelle to Depart as Chief Financial Officer of Eliem Therapeutics, Inc CI
Bob Azelby to Depart as Chief Executive Officer of Eliem Therapeutics, Inc CI
Eliem Therapeutics, Inc. Announces Executive Changes CI
Eliem Therapeutics, Inc. Announces the Resignation of Leone Patterson from the Board of Directors CI
Eliem Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
HC Wainwright Starts Eliem Therapeutics at Buy With $6 Price Target MT
Eliem Therapeutics, Inc. Provides Update on Pipeline Progress CI
SVB Securities Adjusts Eliem Therapeutics' Price Target to $4 From $9, Keeps Outperform Rating MT
Eliem Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Sector Update: Health Care Stocks Weaken in Choppy Session MT
Sector Update: Health Care Stocks Starting to Strengthen in Tuesday Trading MT
Eliem Therapeutics to Discontinue ETX-810 Program for Treatment of Lumbosacral Radicular Pain; Shares Tumble MT
Wall Street Falters Pre-Bell as Pelosi's Expected Taiwan Visit Fuels Geopolitical Uncertainty MT
Top Premarket Decliners MT
Chart Eliem Therapeutics, Inc.
More charts
Eliem Therapeutics, Inc. is a biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. It is developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with therapeutic potential to deliver improved therapeutics for patients with these disorders. Its lead program is ETX-123, a Kv7.2/3 potassium channel opener. Kv7.2/3 has been clinically validated as a therapeutic target for both epilepsy and pain, with further encouraging clinical data in depression. Its ETX-123 lead candidate is an generate new chemical entities designed to harness the efficacy of the Kv7.2/3 channel mechanism while attempting to improve the safety and tolerability relative to earlier molecules, based on its insights into the mechanisms of toxicity and the potency and selectivity profile.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock
  2. Equities
  3. Stock Eliem Therapeutics, Inc. - Nasdaq
  4. News Eliem Therapeutics, Inc.
  5. Sector Update: Health Care Stocks Mixed Premarket Monday